buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
Company Atlas/HealthCare/Aurobindo Pharma
NSE: AUROPHARMA· HealthCareValue · Aug 26Mid cap

Aurobindo Pharma

Value: largest US ANDA portfolio

Last close
₹1,697.70
29 Sept 2026 · reference
1D · 1M
0.0% · +3.2%
price-only
Weight
1.6%
31 Jul 2026 · Aug rank 29
Thesis review
8 Sep 2026
Why We Own, p42
Coverage owner: Research (per book); latest results Q Jun-26Buoyant AIF I Top 30 Holdings - Aug 2026.pdf · p1Buoyant_Why_We_Own_What_We_Own_Sep2026.pdf (portfolio as of 31 July 2026) · p42Screener ↗Tijori ↗NSE ↗
OverviewBusiness & segmentsChartsFinancialsValuationThesisRisks & catalystsCompetitorsResearch & documents
Broker research · 1 report

Sell-side views, extracted from the PDFs on file

Axis SecuritiesHOLDresult update
Aurobindo Pharma Ltd - Result Update: Operational Beat
7 Aug 2026 · Sukhad Kumar Sahu · 11 pp · open PDF ↗
Target
₹1,600
At report
₹1,589+1% printed
Vs our close
−5.8%

Axis Securities downgrades Aurobindo Pharma from BUY to HOLD after a Q1FY27 operational beat on revenue, EBITDA and PAT, citing above-average valuation despite a strong growth outlook across US, Europe, Pen-G, China OSD and the biosimilars/CDMO pipeline. The target price is raised to Rs 1,600 (18x FY28E EPS) from Rs 1,345, implying only 1% upside from CMP.

Thesis
  • Q1FY27 revenue grew 16.3% YoY and 3.4% QoQ to Rs 9,150 Cr, beating Axis estimate of Rs 8,390 Cr by 9.1%, led by broad-based growth in US ($399 Mn, +8.1% YoY), Europe (Rs 2,937 Cr / €267 Mn, +25.6% YoY) and Growth Markets (Rs 1,063 Cr, +37.7% YoY)
  • Gross margin expanded 153 bps YoY to 60.4%; operating EBITDA (ex one-time lease derecognition loss of Rs 43 Cr) grew 20% YoY to Rs 1,924 Cr at 21% margin, beating estimate by 8.8%
  • PAT grew 25.2% YoY to Rs 1,032 Cr, 17.7% ahead of the Rs 877 Cr Axis estimate
  • Management reaffirmed FY27 guidance of double-digit revenue growth, EBITDA margin above 21%, and absolute EBITDA exceeding Rs 8,000 Cr
  • Lannett acquisition ($247 Mn) closed post FTC approval, strengthening complex generics/controlled substances/US government channel presence, with gAdvair launch slated for Aug'26
  • Pipeline optionality from biosimilars (CuraTeQ), TheraNym biologics CMO (anchor client MSD, targeting $150-200 Mn long-term revenue by 2032) and the newly acquired A1 Biochem CRO (targeting 3-5x revenue scaling)
Risks
  • USFDA inspection outcomes issuing Warning Letters/OAI or 483 observations could impact revenue growth
  • Entry of new players may increase pricing pressure in the injectable portfolio
  • Delay in the launch of biosimilars in the market
Q1FY27 highlights
  • Net Sales Rs 9,150 Cr, up 16.3% YoY and 3.4% QoQ, beating Axis estimate by 9.1%
  • EBITDA Rs 1,881 Cr, up 17.3% YoY, margin 20.6% (up 18 bps YoY), beating estimate by 8.8%
  • Reported PAT Rs 1,032 Cr, up 25.2% YoY and 12.1% QoQ, beating estimate by 17.7%
  • EPS of Rs 17.8 vs Axis estimate of Rs 15.0
  • US revenue $399 Mn (Rs 3,770 Cr), up 8.1% YoY; Europe formulations Rs 2,937 Cr (€267 Mn), up 25.6% YoY / 11% YoY constant currency; Growth Markets Rs 1,063 Cr, up 37.7% YoY
  • R&D spend held at Rs 344 Cr (~4% of revenue); effective tax rate 31.9% in Q1FY27, expected to normalise to 28-29% by FY27 end
Catalysts
  • gAdvair launch in the US scheduled for Aug'26
  • PLI scheme incentive disbursements for Pen-G expected between September and March
  • China OSD facility targeted to turn EBITDA positive in FY27
  • TheraNym Unit 1 equipment qualification beginning Nov'26
Broker estimatesUnitFY25FY26FY27EFY28E
Net Sales₹ cr31,72433,65337,52841,739
EBITDA₹ cr6,5836,8468,1069,183
EBITDA Margin%20.820.321.622
Reported PAT₹ cr3,4843,5034,4195,155
EPS₹6060.376.188.8
PERx—21.62118
EV/EBITDAx—10.810.89.1
P/BVx—22.22
ROE%10.79.210.511
RoCE%15.51417.119.5

Valuation: 18x P/E on FY28E EPS. Target price of Rs 1,600/share is derived by valuing Aurobindo at 18x FY28E EPS, up from the earlier valuation of 17x Dec FY27E EPS (Rs 1,345 TP), implying 1% upside from CMP of Rs 1,589. Post Q1FY27 results, Axis cut FY27E/FY28E Revenue by 2.8%/3.1%, EBITDA by 0.9%/3.1%, and PAT by 4.2%/6.4%, while raising the target price to Rs 1,600 from Rs 1,345 and downgrading the rating from BUY to HOLD.

Extraction note: The EPS shown in the Q1FY27 'Key Financials' table (Rs 17.8) differs from the FY26 full-year EPS in the estimates table (Rs 60.3); both are as printed. Recommendation history table on page 7 shows a downgrade from BUY to HOLD on 07-Aug-26 with TP raised from 1,345 to 1,600.

Figures are transcribed from each broker's PDF as printed (units as the broker states them) and are the broker's estimates, not Buoyant's. "Vs our close" recomputes the target against the latest reference close (29 Sept 2026).

SWOT

Strengths · Weaknesses · Opportunities · Threats

Draft
Strengths
  • Earnings inflecting: Q1FY27 PAT +25% YoY and EBITDA margin 21% vs 20.4%; management guides FY27 absolute EBITDA >Rs 8,000 cr (+16% on FY26 Rs 6,870 cr).
  • Europe is now a second engine: Rs 2,937 cr in Q1 (+25.6% YoY) at >20% EBITDA margin per Axis; Growth Markets +37.7%.
  • Optionality from complex/biosimilars: 4 biosimilars already selling in EU/UK, denosumab EMA filing underway, omalizumab filing targeted Q3-2026; TheraNym/CuraTeQ guided to USD 150-200 mn revenue by 2032 at 35-50% EBITDA margin.
  • Backward integration: Pen-G/6-APA plant running 60-70% utilisation in Q4FY26 with a 10,000 MT FY27 target (HSIE, Feb-2026); China plant to exceed 2 bn tablets capacity by end-2026/mid-2027 supporting EU margins.
Weaknesses
  • vs Sun Pharma: Sun trades at a large specialty premium while its US generics fell 9.7% in Q1FY27; Aurobindo offers 21% EPS CAGR at ~19x FY28E with no Revlimid cliff exposure.
  • vs Cipla: Cipla faces a FY27 gRevlimid earnings decline (brokers flag ~30% PAT drop in Q1FY27 preview); Aurobindo's US base is diversified across 737 approved ANDAs plus injectables and had no Revlimid dependence.
Opportunities
  • Advair generic launch via Lannett guided for Aug-2026; Lannett utilisation ramp over 12 months.
  • Omalizumab EMA filing targeted Q3-CY2026; denosumab EMA filing underway; TheraNym Unit 1 qualification Nov-2026.
  • Q2FY27 results (Nov-2026): delivery against >Rs 8,000 cr FY27 EBITDA guidance; interim dividend Rs 4/share already declared.
Threats
  • USFDA inspection outcomes at Eugia/other units (Axis flags as key risk); any OAI/warning letter would hit injectables supply.
  • US injectables pricing pressure from new entrants and Lannett integration (plant at only 40% utilisation) diluting margins.
  • Biosimilar launch delays (denosumab/omalizumab EMA filings) and slow ramp of the Pen-G plant leaving PLI-linked capex under-utilised.

Compiled from the approved one-pager (Why We Own What We Own, 8 Sep 2026): why-we-own → strengths, catalysts → opportunities, key risks → threats, peer caveats → weaknesses. Editorial mapping pending review. · author: compiled from the approved one-pager

Research reports · upload with a check step

0 approved · 0 pending · 0 rejected

Only approved reports are readable from the company page; the reviewer must differ from the uploader. Files are hashed (duplicates skipped) and held in the private store.

Internal evidence

Buoyant sources for this name

  • August 2026 top-30 disclosure — rank 29, HealthCare, Value. Buoyant AIF I Top 30 Holdings - Aug 2026.pdf
  • One-pager, "Why We Own What We Own" — p42, 8 Sep 2026. Buoyant_Why_We_Own_What_We_Own_Sep2026.pdf (portfolio as of 31 July 2026)
  • Sales playbook, Aug 2026 — holdings matrix (PMS/AIF I/AIF II, $31 Jul 2026). Buoyant_Capital_Sales_Playbook_Aug_2026_Full_Holdings.pdf

Original PDFs are in the supplied package on disk; private object storage is not configured, so source pages are referenced, not served.

Company filings

Investor documents (Tijori knowledge base)

annual reports
  • Annual report FY26
  • Annual report FY25
  • Annual report FY24
  • Annual report FY23
  • Annual report FY22
  • Annual report FY21
earnings releases
  • Results Feb26
  • Results May26
  • Results Aug26
  • Results May25
  • Results Aug25
  • Results Nov25
  • Results Mar24
  • Results Jun24
  • Results Sep24
  • Results Dec24
  • Results Mar23
  • Results Jun23
investor presentations
  • Presentation Feb26
  • Presentation May26
  • Presentation Aug26
  • Presentation May25
  • Presentation Aug25
  • Presentation Nov25
  • Presentation Mar24
  • Presentation Jun24
  • Presentation Sep24
  • Presentation Dec24
  • Presentation Mar23
  • Presentation Jun23
conference calls
  • Call Feb26
  • Call May26
  • Call Aug26
  • Call Mar25
  • Call Jun25
  • Call Nov25
  • Call Mar24
  • Call Jun24
  • Call Sep24
  • Call Dec24
  • Call Mar23
  • Call Jun23

Links open the issuer's or exchange's document; fetched only through the user's browser, never by the platform.

Ownership

Shareholding · Jun'26

Promoter51.88%
Indian Promoters48.81%
RPR SONS ADVISORS PRIVATE LIMITED, MRS.P.SUNEELA RANI (JOINTLY HOLDING)33.54%
KAMBAM NITHYANANDA REDDY4.37%
KIRTHI REDDY KAMBAM3.46%
AXIS CLINICALS LIMITED, TRIDENT CHEMPHAR LIMITED, RPR SONS ADVISORS PVT.LTD. (JOINTLY HOLDING)2.86%
M SIVAKUMARAN2.48%
KAMBAM SPOORTHI1.20%
KOTTAMANCHI RAJESWARI0.31%
M SUMANTH KUMAR REDDY0.27%
TRIDENT CHEMPHAR LIMITED0.13%
AXIS CLINICALS LIMITED0.11%
Foreign Promoters3.07%
VENKATA RAMPRASAD REDDY PENAKA3.07%